Despite overall higher earnings in its three business segments combined, healthcare giant Mallinckrodt saw a decline in year over year sales and revenues within its imaging division during the first quarter of 2000 (end-September). The St. Louis-based
Despite overall higher earnings in its three business segments combined, healthcare giant Mallinckrodt saw a decline in year over year sales and revenues within its imaging division during the first quarter of 2000 (end-September). The St. Louis-based company reported total sales of $614 million for the quarter, a 4% increase over sales of $592 million for the same quarter a year ago. Net earnings for the quarter were $38 million, up 19% from first quarter 1999 earnings of $32 million. Mallinckrodt chairman and CEO C. Ray Holman attributed the improvement in profitability to stronger sales of its pulse oximetry, radiopharmaceutical, and pharmaceutical products.
However, Mallinckrodts imaging group reported a 1% decrease in year over year revenues for the quarter, due primarily to lower sales of its x-ray contrast media and diagnostic catheter products. The imaging division recorded $182 million in sales, compared to $184 million for the first quarter of 1999. Quarterly earnings for the division fell 24% to $23 million from earnings of $31 million for the same quarter a year ago.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.